EIF3D and rectal cancer: In our pan-cancer analysis, significant differential expression of EIF3D was observed in breast cancer (BRCA), bile duct cancer (CHOL), colon and rectal cancer (COAD), and HNSC, with a noteworthy overexpression observed across most tumor types (P < 0.01, as depicted in Figure 1A).